home / stock / myov / myov quote
Last: | $26.98 |
---|---|
Change Percent: | -0.04% |
Open: | $26.99 |
Close: | $26.98 |
High: | $27 |
Low: | $26.98 |
Volume: | 2,256,078 |
Last Trade Date Time: | 03/09/2023 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$26.98 | $26.99 | $26.98 | $27 | $26.98 | 2,256,078 | 03-09-2023 |
$26.99 | $26.97 | $26.99 | $26.99 | $26.97 | 1,219,532 | 03-08-2023 |
$26.97 | $26.98 | $26.97 | $26.98 | $26.97 | 819,716 | 03-07-2023 |
$26.97 | $26.96 | $26.97 | $26.98 | $26.95 | 3,067,486 | 03-06-2023 |
$26.95 | $26.98 | $26.95 | $26.98 | $26.95 | 4,386,203 | 03-03-2023 |
$26.95 | $26.97 | $26.95 | $26.99 | $26.95 | 2,441,568 | 03-02-2023 |
$26.96 | $26.96 | $26.96 | $26.97 | $26.95 | 1,343,185 | 03-01-2023 |
$26.96 | $26.97 | $26.96 | $26.97 | $26.95 | 507,498 | 02-28-2023 |
$26.96 | $26.96 | $26.96 | $26.97 | $26.96 | 303,958 | 02-27-2023 |
$26.96 | $26.96 | $26.96 | $26.97 | $26.95 | 454,140 | 02-24-2023 |
$26.96 | $26.97 | $26.96 | $26.98 | $26.94 | 349,343 | 02-23-2023 |
$26.95 | $26.94 | $26.95 | $26.97 | $26.93 | 700,192 | 02-22-2023 |
$26.92 | $26.93 | $26.92 | $26.95 | $26.91 | 651,780 | 02-21-2023 |
$26.97 | $26.93 | $26.97 | $26.97 | $26.93 | 282,714 | 02-20-2023 |
$26.97 | $26.93 | $26.97 | $26.97 | $26.93 | 282,714 | 02-17-2023 |
$26.93 | $26.94 | $26.93 | $26.96 | $26.92 | 509,187 | 02-16-2023 |
$26.95 | $26.93 | $26.95 | $26.96 | $26.93 | 295,339 | 02-15-2023 |
$26.93 | $26.93 | $26.93 | $26.97 | $26.92 | 703,818 | 02-14-2023 |
$26.93 | $26.91 | $26.93 | $27.06 | $26.9 | 2,238,543 | 02-13-2023 |
$26.91 | $26.92 | $26.91 | $26.93 | $26.9 | 980,680 | 02-10-2023 |
News, Short Squeeze, Breakout and More Instantly...
Myovant Sciences Ltd. Company Name:
MYOV Stock Symbol:
NYSE Market:
NEW YORK, NY / ACCESSWIRE / October 19, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myovant Sciences, Ltd. ("Myovant" or "the Company") (NYSE:MYOV). Investors who purchased Myovant securities are encouraged to obtain additional infor...
Third fiscal quarter 2022 total revenue of $100.2 million ; including net product revenue of $61.4 million Net product revenue from U.S. sales of ORGOVYX ® of $48.7 million in third fiscal quarter 2022, with sequential quarterly demand volume ...
MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences PR Newswire ...